Logo

Orion Genomics, Wash U to Co-develop Cancer Tests Based on Methylated DNA

Aug 09, 2005

NEW YORK, Aug. 9 (GenomeWeb News) - Orion Genomics is collaborating with researchers at WashingtonUniversityin St. Louisto discover diagnostic cancer biomarkers, the St. Louis-based company said today.

 

In several collaborations, scientists at Orion and WashingtonUniversitywill study common cancers, including lung, breast, cervical, prostate, and ovarian cancer, to find DNA methylation-based biomarkers of cancer and those that indicate how a cancer will respond to certain therapies.

 

Orion plans to develop tests that detect trace amounts of methylated tumor DNA in tissues such as blood serum, biopsies, and cell scraps, and expects to market them within three years.

Breaking News
The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.